HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $325 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Biogen (NASDAQ:BIIB) and maintained a price target of $325.
July 07, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $325 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a high price target indicates confidence in the company's performance, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100